Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib
In conclusion, among the various combinations studied, rucaparib plus irinotecan was the most synergistic one. Alterations in cell cycle arrest and apoptosis were dependent on MSI status in CRC cells.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Drugs & Pharmacology | Investigational New Drugs | Study